{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:29:09Z","timestamp":1790908149734,"version":"4.1.0"},"reference-count":63,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mycosis fungoides (MF) is the most frequent type of cutaneous T-cell lymphoma, whose diagnosis and study is hampered by its morphologic similarity to inflammatory dermatoses (ID) and the low proportion of tumoral cells, which often account for only 5% to 10% of the total tissue cells. cDNA microarray studies using the CNIO OncoChip of 29 MF and 11 ID cases revealed a signature of 27 genes implicated in the tumorigenesis of MF, including tumor necrosis factor receptor (TNFR)\u2013dependent apoptosis regulators, STAT4, CD40L, and other oncogenes and apoptosis inhibitors. Subsequently a 6-gene prediction model was constructed that is capable of distinguishing MF and ID cases with unprecedented accuracy. This model correctly predicted the class of 97% of cases in a blind test validation using 24 MF patients with low clinical stages. Unsupervised hierarchic clustering has revealed 2 major subclasses of MF, one of which tends to include more aggressive-type MF cases including tumoral MF forms. Furthermore, signatures associated with abnormal immunophenotype (11 genes) and tumor stage disease (5 genes) were identified.<\/jats:p>","DOI":"10.1182\/blood-2002-11-3574","type":"journal-article","created":{"date-parts":[[2003,4,14]],"date-time":"2003-04-14T20:14:33Z","timestamp":1050351273000},"page":"1042-1050","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":145,"title":["Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study"],"prefix":"10.1182","volume":"102","author":[{"given":"Lorraine","family":"Tracey","sequence":"first","affiliation":[{"name":"From the Centro Nacional de Investigaciones Oncolo\u0301gicas, Molecular Pathology Program, Madrid, Spain; the Pathology Department, Hospital Universitario de Getafe, Madrid, Spain; the Department of Hematology and the Institute for Molecular Medicine, St James Hospital, Dublin, Ireland; and the Dermatology and Pathology Department, Hospital 12 de Octubre, Madrid, Spain, representing the Cooperative Cutaneous Lymphoma Group of Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Villuendas","sequence":"additional","affiliation":[{"name":"From the Centro Nacional de Investigaciones Oncolo\u0301gicas, Molecular Pathology Program, Madrid, Spain; the Pathology Department, Hospital Universitario de Getafe, Madrid, Spain; the Department of Hematology and the Institute for Molecular Medicine, St James Hospital, Dublin, Ireland; and the Dermatology and Pathology Department, Hospital 12 de Octubre, Madrid, Spain, representing the Cooperative Cutaneous Lymphoma Group of Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Dotor","sequence":"additional","affiliation":[{"name":"From the Centro Nacional de Investigaciones Oncolo\u0301gicas, Molecular Pathology Program, Madrid, Spain; the Pathology Department, Hospital Universitario de Getafe, Madrid, Spain; the Department of Hematology and the Institute for Molecular Medicine, St James Hospital, Dublin, Ireland; and the Dermatology and Pathology Department, Hospital 12 de Octubre, Madrid, Spain, representing the Cooperative Cutaneous Lymphoma Group of Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Spiteri","sequence":"additional","affiliation":[{"name":"From the Centro Nacional de Investigaciones Oncolo\u0301gicas, Molecular Pathology Program, Madrid, Spain; the Pathology Department, Hospital Universitario de Getafe, Madrid, Spain; the Department of Hematology and the Institute for Molecular Medicine, St James Hospital, Dublin, Ireland; and the Dermatology and Pathology Department, Hospital 12 de Octubre, Madrid, Spain, representing the Cooperative Cutaneous Lymphoma Group of Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Ortiz","sequence":"additional","affiliation":[{"name":"From the Centro Nacional de Investigaciones Oncolo\u0301gicas, Molecular Pathology Program, Madrid, Spain; the Pathology Department, Hospital Universitario de Getafe, Madrid, Spain; the Department of Hematology and the Institute for Molecular Medicine, St James Hospital, Dublin, Ireland; and the Dermatology and Pathology Department, Hospital 12 de Octubre, Madrid, Spain, representing the Cooperative Cutaneous Lymphoma Group of Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Garci\u0301a","sequence":"additional","affiliation":[{"name":"From the Centro Nacional de Investigaciones Oncolo\u0301gicas, Molecular Pathology Program, Madrid, Spain; the Pathology Department, Hospital Universitario de Getafe, Madrid, Spain; the Department of Hematology and the Institute for Molecular Medicine, St James Hospital, Dublin, Ireland; and the Dermatology and Pathology Department, Hospital 12 de Octubre, Madrid, Spain, representing the Cooperative Cutaneous Lymphoma Group of Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis Rodri\u0301guez","family":"Peralto","sequence":"additional","affiliation":[{"name":"From the Centro Nacional de Investigaciones Oncolo\u0301gicas, Molecular Pathology Program, Madrid, Spain; the Pathology Department, Hospital Universitario de Getafe, Madrid, Spain; the Department of Hematology and the Institute for Molecular Medicine, St James Hospital, Dublin, Ireland; and the Dermatology and Pathology Department, Hospital 12 de Octubre, Madrid, Spain, representing the Cooperative Cutaneous Lymphoma Group of Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lawler","sequence":"additional","affiliation":[{"name":"From the Centro Nacional de Investigaciones Oncolo\u0301gicas, Molecular Pathology Program, Madrid, Spain; the Pathology Department, Hospital Universitario de Getafe, Madrid, Spain; the Department of Hematology and the Institute for Molecular Medicine, St James Hospital, Dublin, Ireland; and the Dermatology and Pathology Department, Hospital 12 de Octubre, Madrid, Spain, representing the Cooperative Cutaneous Lymphoma Group of Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Piris","sequence":"additional","affiliation":[{"name":"From the Centro Nacional de Investigaciones Oncolo\u0301gicas, Molecular Pathology Program, Madrid, Spain; the Pathology Department, Hospital Universitario de Getafe, Madrid, Spain; the Department of Hematology and the Institute for Molecular Medicine, St James Hospital, Dublin, Ireland; and the Dermatology and Pathology Department, Hospital 12 de Octubre, Madrid, Spain, representing the Cooperative Cutaneous Lymphoma Group of Madrid"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021300105221600_REF1","doi-asserted-by":"crossref","unstructured":"Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol.2000;18: 2908-2925.","DOI":"10.1200\/JCO.2000.18.15.2908"},{"key":"2020021300105221600_REF2","doi-asserted-by":"crossref","unstructured":"Edelson RL. Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants. J Am Acad Dermatol.1980;2: 89-106.","DOI":"10.1016\/S0190-9622(80)80385-9"},{"key":"2020021300105221600_REF3","doi-asserted-by":"crossref","unstructured":"Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol.1999;155: 483-492.","DOI":"10.1016\/S0002-9440(10)65144-9"},{"key":"2020021300105221600_REF4","doi-asserted-by":"crossref","unstructured":"Murphy M, Fullen D, Carlson JA. Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: experience with an antibody reactive with paraffin-embedded tissue. Am J Dermatopathol.2002;24: 6-16.","DOI":"10.1097\/00000372-200202000-00002"},{"key":"2020021300105221600_REF5","doi-asserted-by":"crossref","unstructured":"Wood GS. Lymphocyte activation in cutaneous T-cell lymphoma. J Invest Dermatol.1995;105: 105S-109S.","DOI":"10.1111\/1523-1747.ep12316249"},{"key":"2020021300105221600_REF6","doi-asserted-by":"crossref","unstructured":"Hall WW, Liu CR, Schneewind O, et al. Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science. 1991;253: 317-320.","DOI":"10.1126\/science.1857968"},{"key":"2020021300105221600_REF7","unstructured":"Wood GS, Schaffer JM, Boni R, et al. No evidence of HTLV-I proviral integration in lymphoproliferative disorders associated with cutaneous T-cell lymphoma. Am J Pathol.1997;150: 667-673."},{"key":"2020021300105221600_REF8","doi-asserted-by":"crossref","unstructured":"Dereure O, Levi E, Vonderheid EC, Kadin ME. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol.2002;118: 949-956.","DOI":"10.1046\/j.1523-1747.2002.01794.x"},{"key":"2020021300105221600_REF9","doi-asserted-by":"crossref","unstructured":"Dereure O, Portales P, Clot J, Guilhou JJ. Decreased expression of Fas (APO-1\/CD95) on peripheral blood CD4+ T lymphocytes in cutaneous T-cell lymphomas. Br J Dermatol.2000;143: 1205-1210.","DOI":"10.1046\/j.1365-2133.2000.03889.x"},{"key":"2020021300105221600_REF10","doi-asserted-by":"crossref","unstructured":"Dummer R, Michie SA, Kell D, et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol.1995;22: 11-17.","DOI":"10.1111\/j.1600-0560.1995.tb00733.x"},{"key":"2020021300105221600_REF11","doi-asserted-by":"crossref","unstructured":"Navas IC, Algara P, Mateo M, et al. p16(INK4a) is selectively silenced in the tumoral progression of mycosis fungoides. Lab Invest.2002;82: 123-132.","DOI":"10.1038\/labinvest.3780405"},{"key":"2020021300105221600_REF12","doi-asserted-by":"crossref","unstructured":"Navas IC, Ortiz-Romero PL, Villuendas R, et al. p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides. Am J Pathol.2000;156: 1565-1572.","DOI":"10.1016\/S0002-9440(10)65028-6"},{"key":"2020021300105221600_REF13","doi-asserted-by":"crossref","unstructured":"Scarisbrick JJ, Woolford AJ, Calonje E, et al. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. J Invest Dermatol.2002;118: 493-499.","DOI":"10.1046\/j.0022-202x.2001.01682.x"},{"key":"2020021300105221600_REF14","doi-asserted-by":"crossref","unstructured":"Qin JZ, Kamarashev J, Zhang CL, Dummer R, Burg G, Dobbeling U. Constitutive and interleukin-7- and interleukin-15-stimulated DNA binding of STAT and novel factors in cutaneous T cell lymphoma cells. J Invest Dermatol.2001;117: 583-589.","DOI":"10.1046\/j.0022-202x.2001.01436.x"},{"key":"2020021300105221600_REF15","doi-asserted-by":"crossref","unstructured":"Nielsen M, Kaltoft K, Nordahl M, et al. Constitutive activation of a slowly migrating isoform of Stat3 in mycosis fungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosis fungoides tumor cell lines. Proc Natl Acad Sci U S A. 1997;94: 6764-6769.","DOI":"10.1073\/pnas.94.13.6764"},{"key":"2020021300105221600_REF16","doi-asserted-by":"crossref","unstructured":"LeBoit PE. Lymphomatoid papulosis and cutaneous CD30+ lymphoma. Am J Dermatopathol.1996;18: 221-235.","DOI":"10.1097\/00000372-199606000-00001"},{"key":"2020021300105221600_REF17","unstructured":"Storz M, Zepter K, Kamarashev J, Dummer R, Burg G, Haffner AC. Coexpression of CD40 and CD40 ligand in cutaneous T-cell lymphoma (mycosis fungoides). Cancer Res.2001;61: 452-454."},{"key":"2020021300105221600_REF18","doi-asserted-by":"crossref","unstructured":"Asadullah K, Haeussler-Quade A, Gellrich S, et al. IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Exp Dermatol.2000;9: 248-251.","DOI":"10.1034\/j.1600-0625.2000.009004248.x"},{"key":"2020021300105221600_REF19","doi-asserted-by":"crossref","unstructured":"Jones D, O'Hara C, Kraus MD, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood. 2000;96: 685-690.","DOI":"10.1182\/blood.V96.2.685"},{"key":"2020021300105221600_REF20","doi-asserted-by":"crossref","unstructured":"Wu KD, Hansen ER. Shortened telomere length is demonstrated in T-cell subsets together with a pronounced increased telomerase activity in CD4 positive T cells from blood of patients with mycosis fungoides and parapsoriasis. Exp Dermatol.2001;10: 329-336.","DOI":"10.1034\/j.1600-0625.2001.100505.x"},{"key":"2020021300105221600_REF21","doi-asserted-by":"crossref","unstructured":"Izban KF, Ergin M, Qin JZ, et al. Constitutive expression of NF-kappa B is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol.2000;31: 1482-1490.","DOI":"10.1053\/hupa.2000.20370"},{"key":"2020021300105221600_REF22","doi-asserted-by":"crossref","unstructured":"Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403: 503-511.","DOI":"10.1038\/35000501"},{"key":"2020021300105221600_REF23","doi-asserted-by":"crossref","unstructured":"Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A. 2001;98: 10787-10792.","DOI":"10.1073\/pnas.191368598"},{"key":"2020021300105221600_REF24","doi-asserted-by":"crossref","unstructured":"Tracey L, Villuendas R, Ortiz P, et al. Identification of genes involved in resistance to interferonalpha in cutaneous T-cell lymphoma. Am J Pathol.2002;161: 1825-1837.","DOI":"10.1016\/S0002-9440(10)64459-8"},{"key":"2020021300105221600_REF25","doi-asserted-by":"crossref","unstructured":"Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med.2002;8: 68-74.","DOI":"10.1038\/nm0102-68"},{"key":"2020021300105221600_REF26","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001."},{"key":"2020021300105221600_REF27","doi-asserted-by":"crossref","unstructured":"Herrero J, Di\u0301az-Uriarte R, Dopazo J. Gene expression data preprocessing. Bioinformatics. 2003;19: 655-656.","DOI":"10.1093\/bioinformatics\/btg040"},{"key":"2020021300105221600_REF28","doi-asserted-by":"crossref","unstructured":"Herrero J, Valencia A, Dopazo J. A hierarchical unsupervised growing neural network for clustering gene expression patterns. Bioinformatics. 2001;17: 126-136.","DOI":"10.1093\/bioinformatics\/17.2.126"},{"key":"2020021300105221600_REF29","doi-asserted-by":"crossref","unstructured":"Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics. 1998;14: 656-664.","DOI":"10.1093\/bioinformatics\/14.8.656"},{"key":"2020021300105221600_REF30","doi-asserted-by":"crossref","unstructured":"Miller RG. Beyond Anova. Toronto, ON, Canada: Chapman & Hall; 1997.","DOI":"10.1201\/b15236"},{"key":"2020021300105221600_REF31","doi-asserted-by":"crossref","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B.1995;57 (series B): 289-300.","DOI":"10.1111\/j.2517-6161.1995.tb02031.x"},{"key":"2020021300105221600_REF32","doi-asserted-by":"crossref","unstructured":"Kohonen T. Self Oganizing Maps. Berlin, Germany: Springer Verlag; 1997.","DOI":"10.1007\/978-3-642-97966-8"},{"key":"2020021300105221600_REF33","doi-asserted-by":"crossref","unstructured":"Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998;281: 1680-1683.","DOI":"10.1126\/science.281.5383.1680"},{"key":"2020021300105221600_REF34","doi-asserted-by":"crossref","unstructured":"Miller LK. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol.1999;9: 323-328.","DOI":"10.1016\/S0962-8924(99)01609-8"},{"key":"2020021300105221600_REF35","doi-asserted-by":"crossref","unstructured":"Duckett CS, Li F, Wang Y, Tomaselli KJ, Thompson CB, Armstrong RC. Human IAP-like protein regulates programmed cell death downstream of Bcl-xL and cytochrome c. Mol Cell Biol.1998;18: 608-615.","DOI":"10.1128\/MCB.18.1.608"},{"key":"2020021300105221600_REF36","doi-asserted-by":"crossref","unstructured":"Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388: 300-304.","DOI":"10.1038\/40901"},{"key":"2020021300105221600_REF37","doi-asserted-by":"crossref","unstructured":"Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. Embo J.1997;16: 6914-6925.","DOI":"10.1093\/emboj\/16.23.6914"},{"key":"2020021300105221600_REF38","doi-asserted-by":"crossref","unstructured":"Rothe M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell. 1995;83: 1243-1252.","DOI":"10.1016\/0092-8674(95)90149-3"},{"key":"2020021300105221600_REF39","doi-asserted-by":"crossref","unstructured":"Maier JK, Lahoua Z, Gendron NH, et al. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J Neurosci.2002;22: 2035-2043.","DOI":"10.1523\/JNEUROSCI.22-06-02035.2002"},{"key":"2020021300105221600_REF40","doi-asserted-by":"crossref","unstructured":"Zapata JM, Krajewska M, Krajewski S, et al. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J Immunol.2000;165: 5084-5096.","DOI":"10.4049\/jimmunol.165.9.5084"},{"key":"2020021300105221600_REF41","doi-asserted-by":"crossref","unstructured":"Schwenzer R, Siemienski K, Liptay S, et al. The human tumor necrosis factor (TNF) receptor-associated factor 1 gene (TRAF1) is up-regulated by cytokines of the TNF ligand family and modulates TNF-induced activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem.1999;274: 19368-19374.","DOI":"10.1074\/jbc.274.27.19368"},{"key":"2020021300105221600_REF42","doi-asserted-by":"crossref","unstructured":"Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell. 1994;78: 681-692.","DOI":"10.1016\/0092-8674(94)90532-0"},{"key":"2020021300105221600_REF43","doi-asserted-by":"crossref","unstructured":"Pullen SS, Labadia ME, Ingraham RH, et al. High-affinity interactions of tumor necrosis factor receptor-associated factors (TRAFs) and CD40 require TRAF trimerization and CD40 multimerization. Biochemistry. 1999;38: 10168-10177.","DOI":"10.1021\/bi9909905"},{"key":"2020021300105221600_REF44","doi-asserted-by":"crossref","unstructured":"Pullen SS, Dang TT, Crute JJ, Kehry MR. CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs): binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem.1999;274: 14246-14254.","DOI":"10.1074\/jbc.274.20.14246"},{"key":"2020021300105221600_REF45","doi-asserted-by":"crossref","unstructured":"Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol.2002;3: 401-410.","DOI":"10.1038\/nrm830"},{"key":"2020021300105221600_REF46","doi-asserted-by":"crossref","unstructured":"Baud V, Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol.2001;11: 372-377.","DOI":"10.1016\/S0962-8924(01)02064-5"},{"key":"2020021300105221600_REF47","doi-asserted-by":"crossref","unstructured":"Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84: 299-308.","DOI":"10.1016\/S0092-8674(00)80984-8"},{"key":"2020021300105221600_REF48","doi-asserted-by":"crossref","unstructured":"Park YC, Ye H, Hsia C, et al. A novel mechanism of TRAF signaling revealed by structural and functional analyses of the TRADD-TRAF2 interaction. Cell. 2000;101: 777-787.","DOI":"10.1016\/S0092-8674(00)80889-2"},{"key":"2020021300105221600_REF49","doi-asserted-by":"crossref","unstructured":"Aldinucci D, Poletto D, Nanni P, et al. CD40L induces proliferation, self-renewal, rescue from apoptosis, and production of cytokines by CD40-expressing AML blasts. Exp Hematol.2002;30: 1283-1292.","DOI":"10.1016\/S0301-472X(02)00921-9"},{"key":"2020021300105221600_REF50","doi-asserted-by":"crossref","unstructured":"Tsubata T, Wu J, Honjo T. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature. 1993;364: 645-648.","DOI":"10.1038\/364645a0"},{"key":"2020021300105221600_REF51","doi-asserted-by":"crossref","unstructured":"English BK, Ihle JN, Myracle A, Yi T. Hck tyrosine kinase activity modulates tumor necrosis factor production by murine macrophages. J Exp Med.1993;178: 1017-1022.","DOI":"10.1084\/jem.178.3.1017"},{"key":"2020021300105221600_REF52","doi-asserted-by":"crossref","unstructured":"Beaty CD, Franklin TL, Uehara Y, Wilson CB. Lipopolysaccharide-induced cytokine production in human monocytes: role of tyrosine phosphorylation in transmembrane signal transduction. Eur J Immunol.1994;24: 1278-1284.","DOI":"10.1002\/eji.1830240606"},{"key":"2020021300105221600_REF53","doi-asserted-by":"crossref","unstructured":"Bosco MC, Curiel RE, Zea AH, Malabarba MG, Ortaldo JR, Espinoza-Delgado I. IL-2 signaling in human monocytes involves the phosphorylation and activation of p59hck. J Immunol.2000;164: 4575-4585.","DOI":"10.4049\/jimmunol.164.9.4575"},{"key":"2020021300105221600_REF54","doi-asserted-by":"crossref","unstructured":"Torigoe T, Saragovi HU, Reed JC. Interleukin 2 regulates the activity of the lyn protein-tyrosine kinase in a B-cell line. Proc Natl Acad Sci U S A. 1992;89: 2674-2678.","DOI":"10.1073\/pnas.89.7.2674"},{"key":"2020021300105221600_REF55","doi-asserted-by":"crossref","unstructured":"Grigorieva I, Grigoriev VG, Rowney MK, Hoover RG. Regulation of c-myc transcription by interleukin-2 (IL-2): identification of a novel IL-2 response element interacting with STAT-4. J Biol Chem.2000;275: 7343-7350.","DOI":"10.1074\/jbc.275.10.7343"},{"key":"2020021300105221600_REF56","doi-asserted-by":"crossref","unstructured":"Gross-Mesilaty S, Reinstein E, Bercovich B, et al. Basal and human papillomavirus E6 oncoprotein-induced degradation of Myc proteins by the ubiquitin pathway. Proc Natl Acad Sci U S A. 1998;95: 8058-8063.","DOI":"10.1073\/pnas.95.14.8058"},{"key":"2020021300105221600_REF57","doi-asserted-by":"crossref","unstructured":"Moynihan TP, Cole CG, Dunham I, O'Neil L, Markham AF, Robinson PA. Fine-mapping, genomic organization, and transcript analysis of the human ubiquitin-conjugating enzyme gene UBE2L3. Genomics. 1998;51: 124-127.","DOI":"10.1006\/geno.1998.5257"},{"key":"2020021300105221600_REF58","doi-asserted-by":"crossref","unstructured":"Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med.1998;188: 1185-1190.","DOI":"10.1084\/jem.188.6.1185"},{"key":"2020021300105221600_REF59","doi-asserted-by":"crossref","unstructured":"Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood. 1998;92: 3410-3415.","DOI":"10.1182\/blood.V92.9.3410"},{"key":"2020021300105221600_REF60","doi-asserted-by":"crossref","unstructured":"Ralfkiaer E, Wollf-Sneedorff A, Thomsen K, Geisler C, Vejlsgaard GL. T-cell receptor gamma delta-positive peripheral T-cell lymphomas presenting in the skin: a clinical, histological and immunophenotypic study. Exp Dermatol.1992;1: 31-36.","DOI":"10.1111\/j.1600-0625.1992.tb00069.x"},{"key":"2020021300105221600_REF61","doi-asserted-by":"crossref","unstructured":"Scheijen B, Griffin JD. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002;21: 3314-3333.","DOI":"10.1038\/sj.onc.1205317"},{"key":"2020021300105221600_REF62","doi-asserted-by":"crossref","unstructured":"Birg F, Rosnet O, Carbuccia N, Birnbaum D. The expression of FMS, KIT and FLT3 in hematopoietic malignancies. Leuk Lymphoma.1994;13: 223-227.","DOI":"10.3109\/10428199409056285"},{"key":"2020021300105221600_REF63","doi-asserted-by":"crossref","unstructured":"Krappmann D, Hatada EN, Tegethoff S, et al. The I kappa B kinase (IKK) complex is tripartite and contains IKK gamma but not IKAP as a regular component. J Biol Chem.2000;275: 29779-29787.","DOI":"10.1074\/jbc.M003902200"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/3\/1042\/1689433\/h81503001042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/3\/1042\/1689433\/h81503001042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:11:11Z","timestamp":1581552671000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/3\/1042\/17330\/Mycosis-fungoides-shows-concurrent-deregulation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,1]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-11-3574","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,8,1]]}}}